Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Debt to Equity (2016 - 2025)

Guided Therapeutics' Debt to Equity history spans 14 years, with the latest figure at -$0.01 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 70.37% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.01, a 70.37% increase, with the full-year FY2025 number at -$0.01, up 70.37% from a year prior.
  • Debt to Equity hit -$0.01 in Q4 2025 for Guided Therapeutics, up from -$0.02 in the prior quarter.
  • Over the last five years, Debt to Equity for GTHP hit a ceiling of -$0.01 in Q1 2021 and a floor of -$0.25 in Q2 2024.
  • Historically, Debt to Equity has averaged -$0.07 across 4 years, with a median of -$0.02 in 2022.
  • Biggest five-year swings in Debt to Equity: crashed 3545.45% in 2021 and later surged 93.19% in 2025.
  • Tracing GTHP's Debt to Equity over 4 years: stood at -$0.02 in 2021, then tumbled by 71.7% to -$0.03 in 2022, then increased by 2.7% to -$0.03 in 2024, then surged by 70.37% to -$0.01 in 2025.
  • Business Quant data shows Debt to Equity for GTHP at -$0.01 in Q4 2025, -$0.02 in Q3 2025, and -$0.02 in Q2 2025.